Union health minister urges graduates in Chandigarh to combine technological excellence with compassion in medical practice
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
Rs. 40 cr buyback, 200% dividend announced
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
Subscribe To Our Newsletter & Stay Updated
